The presentation itself is unlikely to move the stock materially unless it reveals unexpected efficacy or safety signals. Traders should watch for the actual presentation on May 30 and any subsequent analyst notes. The key catalyst remains the FDA's NDA decision on lorundrostat, which will determine the stock's trajectory.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 19 $26.03entry
- T+1 · 6mo ago +9.22%α +8.18% · $28.43
- T+5 · 6mo ago +14.93%α +12.68% · $29.92
- T+20 · 5mo ago −3.46%α −4.44% · $25.13
- T+60 · 3mo ago +0.23%α −6.06% · $26.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mineralys Therapeutics announced that new data from its Phase 3 LAUNCH-HTN trial of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease will be presented at ESH 2026 on May 30. The oral presentation highlights the drug's efficacy and safety profile, supporting its NDA under FDA review. This is a routine scientific conference presentation with no new clinical data released in the filing, making it a modest positive catalyst for awareness but not a material event.
Key Facts
- Oral presentation of Phase 3 LAUNCH-HTN data at ESH 2026 on May 30, 2026
- Trial enrolled adults with uncontrolled hypertension on 2-5 medications, randomized to placebo, lorundrostat 50 mg, or 50 mg with optional up-titration to 100 mg
- Primary endpoint: change from baseline in systolic BP at 6 weeks vs placebo
- NDA for lorundrostat is under FDA review
- Lorundrostat has 374-fold selectivity for aldosterone synthase vs cortisol synthase in vitro
Financial Impact
No financial data disclosed; event is a scientific presentation, not a regulatory decision or financial update
Risk Factors
- FDA may issue a Complete Response Letter (CRL) for lorundrostat, delaying or denying approval
- Competition from other aldosterone synthase inhibitors (e.g., baxdrostat) could limit market share
- Clinical data may not replicate in broader populations or show unexpected safety issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297012 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers